Keros Therapeutics plunges as dosing halted in trial due to safety concerns

Keros Therapeutics

12/12/2024 11:29

** Shares of drug developer Keros Therapeutics  KROS.O  fall
~71% to $20 premarket
    ** KROS says it has halted dosing of 3.0 mg and 4.5 mg doses
of its high blood pressure treatment in a mid-stage study due to
fluid buildup around the heart
    ** Dosing in the 1.5 mg/kg arm will continue after a
risk-benefit review by an independent monitoring committee -
KROS
    ** Co has notified the U.S. FDA about it and expects to
present data from all treatment arms in Q2 2025 - KROS
    ** As of last close, stock has fallen 25.7% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))